Published in Neoplasma on January 01, 1974
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Ann Oncol (2010) 1.14
Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study. Neoplasma (2005) 0.94
Immunosuppression with cyclophosphamide: effect on antibody plaque-forming spleen cells and on hemolytic antibodies production. Neoplasma (1972) 0.80
Phase II study of 4'-epi-doxorubicin in patients with untreated, extensive small cell lung cancer. South-East European Oncology Group (SEEOG). Med Oncol Tumor Pharmacother (1990) 0.80
Ciprofloxacin plus vancomycin versus ceftazidime plus gentamicin in the treatment of pneumonia in granulocytopenic patients with or without venous catheters. Short communication. Chemotherapy (1992) 0.80
Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer. Neoplasma (2009) 0.79
Adjuvant clodronate therapy in patients with locally advanced breast cancer--long term results of a double blind randomized trial. Slovak Clodronate Collaborative Group. Neoplasma (2000) 0.79
Therapy of P388 leukemia with benzaldehyde. Neoplasma (1988) 0.78
Gemcitabine plus cisplatine and paclitaxel (GCP) in second-line treatment of germ cell tumors (GCT): a phase II study. Neoplasma (2005) 0.78
Paclitaxel, bleomycin, etoposide, and cisplatin (T-BEP) as initial treatment in patients with poor-prognosis germ cell tumors (GCT): a phase II study. Neoplasma (2007) 0.78
Netilmicin plus ceftriaxone versus amikacin plus ceftriaxone in the treatment of infections in granulocytopenic patients. Chemotherapy (1992) 0.77
Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients. Chemotherapy (1991) 0.75
Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Phase II study. Support Care Cancer (2005) 0.75
National cancer control programs and setting priorities. Cancer Detect Prev (1986) 0.75
[Chronic myelocytic leukemia. Is the insufficient treatment at the terminal stage a reason for changing therapeutical tactics of the chronic phase?]. Vnitr Lek (1974) 0.75
[Various antibiotics in the monotherapy and combined therapy of infections in cancer patients. Retrospective study of 290 patients]. Cas Lek Cesk (1991) 0.75
Alteration of SRBC immunogenicity by cytostatics (Ypenyl and Cytembena). Neoplasma (1973) 0.75
Treatment of the blastic phase of chronic myeloid leukaemia. A question to solve. Haematologica (1972) 0.75
Carboplatin and cyclophosphamide in the treatment of metastatic seminoma. Neoplasma (2000) 0.75
[Effectiveness of cisplatin with continuous infusion of 5-fluorouracil in neoadjuvant chemotherapy of carcinoma of the oral cavity]. Bratisl Lek Listy (1992) 0.75
Identical karyotypes in acquired drug-resistant sublines of Yoshida sarcoma. Neoplasma (1974) 0.75
Histocompatible leukocyte transfusion during granulocytopenia. Neoplasma (1971) 0.75
Activity of epirubicin and dibromodulcitol in advanced breast cancer. Results of the South-East European Oncology Group Study. Oncology (1988) 0.75
Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Pilot study phase I. Neoplasma (2005) 0.75
Organization of cancer care in Slovakia. Arch Geschwulstforsch (1989) 0.75
[Peroral ciprofloxacin in the therapy of infections in oncology patients]. Cas Lek Cesk (1990) 0.75
Blastic crisis of chronic myelogenous leukaemia. Neoplasma (1969) 0.75
Immunosuppression with thyminalkylamine (Ypenyl Spofa): effect on antibody plaque-forming spleen cells. Neoplasma (1972) 0.75
Sequential intermediate high-dose therapy with etoposide, ifosfamide and cisplatin for patients with germ cell tumors. Neoplasma (2000) 0.75
Treatment of adult acute lymphoblastic leukemia: results of two trials. Neoplasma (1981) 0.75
Treatment of acute lymphoblastic leukemia in children. Long-term results of two trials. Neoplasma (1983) 0.75
[Initial experience with fluconazole, a new triazole antimycotic agent, in oncology patients]. Cas Lek Cesk (1990) 0.75
Single versus combination chemotherapy of L1210 leukemia. Neoplasma (1980) 0.75
Determination of suramin in clinical samples using HPLC. Neoplasma (1991) 0.75
Candidosis, aspergillosis and zygomycosis in an oncology department. Mycoses (1993) 0.75
[Toxicity of cisplatin with continuous infusion of 5-fluorouracil in neoadjuvant chemotherapy of carcinoma of the oral cavity]. Bratisl Lek Listy (1989) 0.75
Immunosuppression with Cytembena: effect on antibody plaque-forming spleen cells and on hemolytic antibodies production. Neoplasma (1973) 0.75
Fluconazole in the treatment of mycotic oropharyngeal stomatitis and esophagitis in neutropenic cancer patients. Chemotherapy (1991) 0.75
Combined chemoimmunotherapy of L5178Y lymphoma. Neoplasma (1978) 0.75